ArticleEndocrine2017
Fatty liver as a risk factor for progression from metabolically healthy to metabolically abnormal in non-overweight individuals.
Article in Endocrine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 47 citations in OpenAlex.
- Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus.Journal of diabetes investigation · 2023Trial
- Association Between Hepatic Steatosis and Deterioration of Metabolic Health in Obese Individuals: A 12-Year Follow-Up of the Tehran Lipid and Glucose Study.Endocrinology, diabetes & metabolism · 2026Article
- Impact of Change, Fluctuation, or Variability in Weight on the Risk of Nonalcoholic Fatty Liver Disease in General Population: A Systematic Review and Meta-Analysis.Health science reports · 2025Article
- Association between non-alcoholic fatty liver disease and metabolically healthy deterioration across different body shape phenotypes at baseline and change patterns.Scientific reports · 2022Article
- Metabolically healthy obesity: Is it really healthy for type 2 diabetes mellitus?World journal of diabetes · 2022Review
- Prediction of Metabolic Disorders Using NMR-Based Metabolomics: The Shanghai Changfeng Study.Phenomics (Cham, Switzerland) · 2021Article
- Metabolically healthy obesity is associated with longitudinal changes in high-density lipoprotein cholesterol in Chinese adults.Eating and weight disorders : EWD · 2021Article
- Short-Term Changes in Metabolically Healthy Overweight/Obesity Status Impact the Susceptibility to Type 2 Diabetes in Chinese Adults.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
- Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis.Journal of gastroenterology · 2020Article
- Lipophagy Impairment Is Associated With Disease Progression in NAFLD.Frontiers in physiology · 2020Article
- Association of [Diabetology & metabolic syndrome · 2020Article
- Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation.Translational gastroenterology and hepatology · 2020Review
- Metabolically healthy obesity: facts and fantasies.The Journal of clinical investigation · 2019Review
- Fasting triglycerides and glucose index is more suitable for the identification of metabolically unhealthy individuals in the Chinese adult population: A nationwide study.Journal of diabetes investigation · 2019Article
- Obesity genetics and cardiometabolic health: Potential for risk prediction.Diabetes, obesity & metabolism · 2019Review
- Clinic, Anthropometric And Metabolic Changes In Adults With Class III Obesity Classified As Metabolically Healthy And Metabolically Unhealthy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019Article
- Nonalcoholic fatty liver disease is an early predictor of metabolic diseases in a metabolically healthy population.PloS one · 2019Article
- The role of NAFLD in cardiometabolic disease: an update.F1000Research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRecent studies identified that metabolically abnormal non-obese phenotype is a risk factor for cardiovascular diseases. However, little is known about risk factor for progression from metabolically healthy non-overweight to metabolically abnormal phenotype. We hypothesized that fatty liver had a clinical impact on progression from metabolically healthy non-overweight to metabolically abnormal phenotype.
methodsIn this retrospective cohort study, 14,093 Japanese (7557 men and 6736 women), who received the health-checkup program from 2004 to 2012, were enrolled. Overweight and obesity were defined as body mass index 23.0-25.0 and ≥25.0 kg/m
resultsOver the median follow-up period of 5.3 years, 873 metabolically healthy non-overweight, 512 metabolically healthy overweight and 536 metabolically healthy obesity individuals progressed to metabolically abnormal. The adjusted hazard risks of fatty liver on progression were 1.49 (95% confidence interval 1.20-1.83, p = 0.005) in metabolically healthy non-overweight, 1.37 (1.12-1.66, p = 0.002) in metabolically healthy overweight and 1.38 (1.15-1.66, p < 0.001) in metabolically healthy obesity, after adjusting for age, sex, alcohol, smoking, exercise, impaired fasting glucose, hypertension, hypertriglyceridemia, low high density lipoprotein-cholesterol concentration, and abdominal obesity.
conclusionsFatty liver is an independent risk factor for progression from metabolically healthy status to metabolically abnormal phenotype, even in non-overweight individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.